Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.61 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.61 |
| ▸ | CDK1 | P06493 | 6/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.61 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.61 |
| ▸ | CDK9 | P50750 | 5/20 | 0.61 |
| ▸ | JUN | P05412 | 3/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.59 |
| ▸ | IKBKB | O14920 | 3/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633294 | 0.94 | CDK2 (0.65) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1633841 | 0.88 | CDK2 (0.58) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1632090 | 0.87 | CDK2 (0.62) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1633718 | 0.85 | CDK2 (0.66) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1631876 | 0.84 | CDK2 (0.51) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1632249 | 0.84 | CCNB2 (0.53) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1631220 | 0.82 | MAPK10 (0.60) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1633414 | 0.82 | CDK2 (0.70) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1633771 | 0.81 | CDK2 (0.50) | CDK2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL1633492 | 0.81 | CDK2 (0.49) | CDK2CCNB2CDK1CCNB1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK2 29/4885CCNB2 935/4885CDK1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.